You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Serum DBI and biomarkers of neuroinflammation in Alzheimer’s disease and delirium
Contributor:
Conti, Elisa;
Andreoni, Simona;
Tomaselli, Davide;
Storti, Benedetta;
Brovelli, Francesco;
Acampora, Roberto;
Da Re, Fulvio;
Appollonio, Ildebrando;
Ferrarese, Carlo;
Tremolizzo, Lucio
Published:
Springer Science and Business Media LLC, 2021
Published in:
Neurological Sciences, 42 (2021) 3, Seite 1003-1007
Language:
English
DOI:
10.1007/s10072-020-04608-x
ISSN:
1590-1874;
1590-3478
Origination:
Footnote:
Description:
Abstract Background Alzheimer’s disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD. Methods A total of n = 30 AD patients were recruited together with n = 30 DEL patients and n = 15 healthy controls (CTRL). Serum diazepam binding inhibitor (DBI), IL-17, IL-6, and TNF-α were assessed by ELISA. Results DBI serum levels were increased in AD patients with respect to CTRL (+ 81%), while DEL values were 70% higher than AD. IL-17 was increased in DEL with respect to CTRL (+ 146%), while AD showed dispersed values and failed to reach significant differences. On the other hand, IL-6 showed a more robust increase in DEL with respect to the other two groups (+ 185% and + 205% vs. CTRL and AD, respectively), and TNF-α failed to show any change. Conclusions DBI may be a very promising candidate for AD, perhaps marking psychomotor DEL-like symptoms, in view of developing future helping tool for practicing physicians. Furthermore, DBI rise in DEL offers novel cues for a better comprehension of the pathogenesis of this potentially fatal condition.